Aion Therapeutic Inc. (CSE: AION) (” Aion Therapeutic ” or the ” Company “) announced today that it has filed 4 new patent applications related to preparations of medicinal and psychedelic mushrooms. The patent applications include use of medicinal mushrooms for the treatment of human cancers including breast cancer, use of combination medical cannabis and medicinal mushroom preparations for the treatment of interstitial cystitis and other bladder diseases, and methods for producing emulsions and nano-emulsions for increasing bioavailability in these formulations. These new additions increase our intellectual property portfolio to a current total of 9 patent applications with more expected in the very near future.

Dr. Herbert A. Fritsche , Chief Science Officer of Aion Therapeutic and former Professor and Director of Clinical Chemistry at the University of Texas , MD Anderson Cancer Center, stated, “Based on these recent discoveries, we believe that it may be possible to improve upon the effectiveness of standard treatments for certain cancers including breast cancer as well as offering a new therapy for the painful chronic condition known as interstitial cystitis.” Dr. Fritsche continued, “We intend to announce the details of these very exciting discoveries now that the patents have been filed.”

Graham Simmonds , Executive Vice Chair and CEO of Aion Therapeutic, commented, “I commend our medical and science teams, led by Dr. Stephen Barnhill and Dr. Herbert Fritsche for creating a robust intellectual property portfolio based on a sound patent strategy. In conjunction with our licensed medical cannabis partner Apollon Formularies Jamaica, Ltd, Aion is leveraging our unique position in a powerful way to combine medical cannabis and medicinal mushroom compounds for the treatment of serious diseases including cancer.” Mr. Simmonds continued, “In addition, Aion will be utilizing psilocybin with certain cannabinoids to treat additional conditions such as major depressive disorder (MDD) at our new Aion Center for Psychedelic Psychiatry directed by Dr. Winston De La Haye in Jamaica . Strategically locating our operations in Jamaica allows Aion to operate and conduct clinical trials in a federally legal environment and thereby having a significant head start on patentable therapeutic formulation discoveries combining mushrooms (including psilocybin) and tetrahydrocannabinol (THC) with other medicinal mushroom and medical cannabis compounds while this type of combinatorial research with psilocybin remains illegal in most of the world.”

About Aion Therapeutic Inc.

Aion Therapeutic Inc. through its wholly-owned subsidiary, AI Pharmaceuticals Jamaica Limited, is in the business of research and development, treatment, data mining and state-of-the-art artificial intelligence (machine learning) techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), natural psychedelic formulations (Ayahuasca), and other medicinal plants in a legal environment for this type of discovery. In addition, Aion Therapeutic is creating a strong international intellectual property portfolio related to its discoveries.

DISCLAIMER & READER ADVISORY

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “may”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include regulatory and other third-party approvals; licensing and other risks. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/aion-therapeutic-files-4-new-patent-applications-including-for-the-treatment-of-human-cancers-301245604.html

SOURCE Aion Therapeutic Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2021/11/c5137.html

News Provided by Canada Newswire via QuoteMedia

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), today announced the closing of its previously announced marketed public offering of 5,000,000 subordinate voting shares in the United States and Canada (the “Offering”) at a public offering price of C$50.00 per share ( $39.63 per share after giving effect to the conversion rate published by Bloomberg at 4:30pm ET on April 7, 2021 to convert Canadian dollars to U.S. dollars). In connection with the closing of the Offering, the underwriters exercised in full their option to purchase an additional 750,000 subordinate voting shares. As a result, the gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by Trulieve, were C$287.5 million (or $227.9 million after giving effect to the conversion rate denoted above).

The Offering was conducted through a syndicate of underwriters led by Canaccord Genuity, as sole book-running manager, and included Cormark Securities Inc., as co-lead manager, as well as ATB Capital Markets Inc., Echelon Wealth Partners Inc., Eight Capital and PI Financial Corp. All of the shares in the Offering were sold by Trulieve. Trulieve intends to use the net proceeds from the Offering primarily to fund Trulieve’s business ‎development and for general working capital purposes‎.

Keep reading... Show less

Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or “ Ayurcann ”), is pleased to announce that the Company intends to complete a non-brokered private placement (the “Financing” ) of up to 2,645,503 units (the “Units” ) at a price of $0.189 per Unit. Each Unit will consist of one common share ( “Common Share” ) of the Company and one-half of a common share purchase warrant ( “Warrant” ), with each whole Warrant entitling the holder to acquire one additional Common Share at an exercise price of $0.38 per Common Share for a period of 36 months from the closing date ( “Closing Date” ) of the Financing, for gross proceeds of up to $500,000 .

The Company will have an option, prior to the closing date, to upsize the offering with the sale of an additional 25% of Units, accounting to aggregate proceeds of up to $625,000.

Keep reading... Show less

Lobe invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce that it has been invited to present at the Emerging Growth Conference on April 14, 2021.

Keep reading... Show less

Company is strategically building a diverse edibles portfolio with taste-forward and effects-driven products to cater to market and consumer needs

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, today announced the launch of Wonder Wellness (“Wonder”) Gummies and availability in Illinois. The new low-dose edibles are enhanced with botanicals to complement the overall cannabis experience, and their simple packaging communicates desired effects so wellness-minded category newcomers can consume with confidence to add cannabis as a part of their daily lifestyles.

Keep reading... Show less

INDVR Brands Inc. (CSE: IDVR) (the “Company” or “INDVR Brands” or “INDVR”), a premier cannabis brand, consolidator and edibles retailer, proudly announces it has signed a Letter of Intent (“LOI”) with BevCanna Enterprises Inc. (“BevCanna”) to produce and distribute certain HONU THC infused and award-winning edible products to retail locations across Canada. The new partnership marks INDVR’s first introduction to the Canadian cannabis market and its first international expansion.

With the THC infused product segment making up a growing percentage of the cannabis consumed in Canada, now is the ideal time to introduce our HONU brand into an edibles market estimated at approximately $1.6 billion annually,” said Joshua Mann, INDVR’s CEO. “Our dedication to product quality and consistency is our defining factor in producing some of the most trusted products in Washington and Oregon states, and we are excited to start building the same brand-loyal following across Canada.”

Keep reading... Show less